BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/21/2025 9:22:10 AM | Browse: 31 | Download: 88
 |
Received |
|
2024-11-15 10:45 |
|
Peer-Review Started |
|
2024-11-15 10:45 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-12-13 08:26 |
|
Revised |
|
2024-12-16 15:36 |
|
Second Decision |
|
2024-12-25 02:48 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-12-25 12:29 |
|
Articles in Press |
|
2024-12-25 12:29 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-01-02 02:44 |
|
Publish the Manuscript Online |
|
2025-01-21 09:22 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Respiratory System |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Therapeutic insights into epidermal growth factor receptor/reactive oxygen species proto-oncogene 1-receptor co-mutated non-small cell lung cancer: Crizotinib as a promising option
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yan Zhou, Bo-Tao Xu, Hai-Ying Zhou and Zhong-Tu Shang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yan Zhou, Assistant Professor, MD, Department of Hepatobiliary surgery, Zhuji People's Hospital, No. 9 Jianmin Road, Taozhu Street, Zhuji 311800, Zhejiang Province, China. 13606850272@163.com |
| Key Words |
Adenocarcinoma; Crizotinib; Genetic heterogeneity; Lung cancer; Mutation; Personalized medicine |
| Core Tip |
Epidermal growth factor receptor (EGFR)/ reactive oxygen species proto-oncogene 1-receptor (ROS1) co-mutations in non-small cell lung cancer (NSCLC) are rare and present distinct therapeutic challenges. This case report demonstrates that ROS1 inhibition with crizotinib achieved superior disease control compared to EGFR-targeted therapy, underscoring the need for individualized treatment strategies that may benefit from biomarker guidance to identify the primary oncogenic driver. Tumor genetic heterogeneity could further affect therapeutic responses, highlighting the importance of advanced sequencing techniques in optimizing treatment plans. Larger studies are crucial to establish effective treatment protocols for NSCLC patients with EGFR/ROS1 co-mutations, with the potential to significantly improve survival outcomes in this complex patient population. |
| Publish Date |
2025-01-21 09:22 |
| Citation |
<p>Zhou Y, Xu BT, Zhou HY, Shang ZT. Therapeutic insights into epidermal growth factor receptor/reactive oxygen species proto-oncogene 1-receptor co-mutated non-small cell lung cancer: Crizotinib as a promising option. <i>World J Clin Oncol</i> 2025; 16(3): 103297</p> |
| URL |
https://www.wjgnet.com/2218-4333/full/v16/i3/103297.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v16.i3.103297 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
